1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Delayed London Stock Exchange  -  11:35 2022-08-12 am EDT
10712.00 GBX   +1.96%
08/12Seagen loses arbitration against Daiichi Sankyo over drug technology
RE
08/12Seagen loses arbitration ruling against Daiichi Sankyo
RE
08/12European Stocks Close Higher After UK GDP, Eurozone Industrial Production Data
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sanofi, GSK variant-specific COVID shot found effective against Omicron

06/24/2022 | 04:44am EDT
FILE PHOTO: VivaTech conference dedicated to innovation and startups at Porte de Versailles exhibition center in Paris

PARIS/LONDON (Reuters) - Late-stage data on an experimental COVID-19 vaccine from Sanofi and GSK has showed the shot confers protection against the Omicron variant of the virus, the companies said on Friday.

The so-called bivalent vaccine targets the Beta variant - first identified in South Africa - as well as the original Wuhan strain of the virus.

In a trial involving 13,000 adults, the vaccine demonstrated an efficacy rate of 64.7% against symptomatic COVID, and 72% efficacy against infections specifically caused by the Omicron variant.

When used in people who previously had COVID, the results were stronger. The vaccine generated an efficacy rate of 75.1% against symptomatic COVID and 93.2% in Omicron-confirmed symptomatic cases, the companies said.

"Sanofi-GSK's vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation," Sanofi said in a statement.

Sanofi's Paris-listed shares and GSK's London-listed shares were both up more than 1% in morning trading.

Earlier this month, the bivalent vaccine showed potential in two trials to protect against the virus' main variants of concern - the Omicron BA.1 and BA.2 strains - when used as a booster shot.

Sanofi and GSK, two of the world's biggest vaccine makers, are hoping to gain a foothold in the market for next-generation variant-focused COVID shots, after falling behind competitors including Moderna, AstraZeneca and Pfizer-BioNTech, in the original race to contain the pandemic.

The new data supporting the bivalent vaccine will be submitted to regulatory authorities with the hope of making the shot available later this year, the companies said on Friday.

Sanofi and GSK's original COVID vaccine is already under review by the European Medicines Agency.

The companies have bet that this bivalent vaccine moulded on the now-supplanted Beta variant will confer broad protection against future viral strains on the basis that Beta expresses similar mutations across multiple variants of concern, including Omicron.

(Reporting by Tassilo Hummel in Paris nd Natalie Grover in London; Editing by Clarence Fernandez and Edmund Blair)

By Natalie Grover


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.96% 10712 Delayed Quote.23.44%
BIONTECH SE 1.11% 160.35 Delayed Quote.-37.80%
DOW JONES AFRICA TITANS 50 INDEX 0.04% 475.25 Real-time Quote.-11.14%
DOW JONES SOUTH AFRICA(ZAR) -0.48% 1989.91 Real-time Quote.0.75%
GSK PLC 3.57% 1450 Delayed Quote.-11.78%
MODERNA, INC. -0.37% 171.18 Delayed Quote.-32.60%
PFIZER, INC. 3.77% 50.11 Delayed Quote.-15.14%
S&P AFRICA 40 INDEX -0.18% 156.88 Real-time Quote.-10.23%
SANOFI 0.84% 85.46 Real-time Quote.-3.52%
All news about ASTRAZENECA PLC
08/12Seagen loses arbitration against Daiichi Sankyo over drug technology
RE
08/12Seagen loses arbitration ruling against Daiichi Sankyo
RE
08/12European Stocks Close Higher After UK GDP, Eurozone Industrial Production Data
MT
08/12Sanofi Says First Patient Enrolled in Study to Investigate Protection Against Respirato..
MT
08/12Guardant Health Says FDA Approved Liquid Biopsy Test as Companion Diagnostic for Lung C..
MT
08/12Enhertu approved in the US as the first HER2-directed therapy for patients with previou..
AQ
08/12ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directe..
BU
08/12ASTRAZENECA : Enhertu approved in the US as the first HER2-directed therapy for patients w..
PU
08/12AstraZeneca, Daiichi Sankyo Receive FDA Approval for Lung Cancer Drug
MT
08/12AstraZeneca's Lung Cancer Drug Secures US FDA's Nod
MT
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 44 198 M - -
Net income 2022 4 471 M - -
Net Debt 2022 24 385 M - -
P/E ratio 2022 46,3x
Yield 2022 2,27%
Capitalization 201 B 201 B -
EV / Sales 2022 5,10x
EV / Sales 2023 4,73x
Nbr of Employees 83 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 129,86 $
Average target price 144,14 $
Spread / Average Target 11,0%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC23.44%201 219
JOHNSON & JOHNSON-3.37%434 603
ELI LILLY AND COMPANY11.53%292 730
PFIZER, INC.-15.14%281 235
ROCHE HOLDING AG-16.91%275 562
ABBVIE INC.5.32%252 131